industry
EU rules may be stifling Britain’s biotech industry
November 19, 2018Sales and Marketing EU, biotech, britain, funding, grants, industry
EU rules are stifling Britain’s biotech industry, according to companies who talked to British newspaper The Daily Telegraph. The newspaper …
Health innovation system is broken and failing patients, new report argues
October 15, 2018Sales and Marketing IP, industry, intellectual property, priofit, research
The pharmaceutical industry is incentivised to set high prices and deliver short-term returns to shareholders, rather than focusing on riskier, …
Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
‘Rejuvenated’ pharma manufacturing set for 2016 comeback
January 4, 2016Manufacturing and Production, Sales and Marketing Employment, industry, manufacturing, patent cliff, pharma, production
The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in …
Pharma industry to deliver strong growth – despite price pressure
September 7, 2015Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry
The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …
John LaMattina: Pharma’s reputation continues to suffer – what can be done to fix it?
February 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bad pharma, Goldacre, John LaMattina, industry, transparency
You don’t have too look far to find unflattering articles about the pharmaceutical industry. What was previously the domain of …
The future is bright – but don’t rely on emerging markets
November 16, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, emerging markets, industry, pwC
The pharma industry could be “on the cusp of a golden era” of renewed productivity and earnings – but only …
Changing business models top pharma concerns
July 16, 2010Sales and Marketing Cegedim, industry, survey
The changing face of pharma business models is the main thing keeping US executives awake at night, according to a …
Digital Pharma: Social media an ‘enigma’ for pharma
July 15, 2010Medical Communications Cegedim, Digital Pharma blog, digital pharma, industry, social media
The vast majority of pharma companies now use social media in one form or another, but it is unclear how …
No sign of revival in R&D productivity
June 30, 2010Research and Development drug development, industry, research
New data on the performance of the pharmaceutical industry shows efforts to raise productivity have not yet made an impact. …
Let’s avoid further stand-offs, says Witty
June 22, 2010Research and Development, Sales and Marketing EFPIA, Greece, industry, pricing
Pharma will need to find new ways of working with European governments in order to avoid further crises as witnessed …
R&D: a new world order
June 16, 2010Manufacturing and Production, Research and Development industry, job cuts, research, research and development
Big pharma is today demolishing the in-house drug discovery and research structures built up over the last decade, and is …
Spain to cut prescription drug prices
May 19, 2010Sales and Marketing Spain, industry, prices
The Spanish government will cut the prices of patented prescription drugs from 1 August in a bid to save 1.3 …
Greece’s crisis could hit European prices
May 6, 2010Sales and Marketing Greece, industry, parallel trade, prices
GlaxoSmithKline’s chief executive Andrew Witty has warned that the economic crisis in Greece could have a knock-on effect across Europe, …
Brennan rejects generics diversification model
February 11, 2010Sales and Marketing AstraZeneca, biosimilars, em, generics, industry
AstraZeneca’s chief executive David Brennan has rejected the strategy of diversification into generics and biosimilars being pursued by many of …
